Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
Abstract NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population. Tesamorelin has been demonstrated to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. We further showed that tesamorelin downregulated hepatic gene sets involved in...
Saved in:
Main Authors: | Lindsay T. Fourman, Takara L. Stanley, James M. Billingsley, Shannan J. Ho Sui, Meghan N. Feldpausch, Autumn Boutin, Isabel Zheng, Colin M. McClure, Kathleen E. Corey, Martin Torriani, David E. Kleiner, Colleen M. Hadigan, Raymond T. Chung, Steven K. Grinspoon |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/968ba8285b7d4c9dac1b0917f40794e7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
by: Bedimo R
Published: (2011) -
Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD
by: Lorena Pantano, et al.
Published: (2021) -
NAFLD in the Elderly
by: Alqahtani SA, et al.
Published: (2021) -
Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
by: Chunye Zhang, et al.
Published: (2021) -
NAFLD in type 1 diabetes: overrated or underappreciated?
by: Jonathan Mertens, et al.
Published: (2021)